This is an exciting addition to my recent interview with Accellta’s CEO, Dr. Itzchak Angel, who highlighted Accellta’s unique technologies for enabling large scale growth of cells in suspension. This interview features insights from Eran Cohen, Accellta’s head of business development and intellectual property (IP) officer.
BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.
In this interview with Tony Veverka, Chief Group Executive of BioEden, Mr. Veverka discusses how dental stem cells will impact our future. BioEden is a global stem cell storage company with laboratories in the UK and USA and sales operations in 19 countries. BioEden is also the world’s first international biobank company to collect, assess, and cryogenically store living stem cells from deciduous baby teeth.
RoosterBio has announced the launch of the Regenerative Medicine (RM) industry’s first xeno-free (XF) hMSC cell banks to advance and simplify stem cell biomanufacturing. By incorporating XF starting materials at early stages, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs. Due of the importance of this announcement, I followed up with Dr. Priya Baraniak, Director of BD & Strategic Marketing at RoosterBio, to further explore details of the launch. [Read more…]
Founded in 2011, Okyanos (pronounced “Oh – key – AH – nos”) is an innovative stem cell therapy provider that specializes in treating patients with congestive heart failure (CHF) and other chronic conditions. The literary name Okyanos, the Greek God of the river Okyanos, symbolizes the restoration of blood flow. Okyanos Cell Therapy delivers a mixed population of fat (adipose) derived stem and regenerative cells (ADRCs) using internationally-approved technology to patients with chronic, degenerative conditions. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. [Read more…]
This is an interview with Philip Askenase, MD, Professor of Medicine and Pathology at Yale University School of Medicine. Dr. Askenase is an expert in the effector properties of exosomes who is now beginning to study mesenchymal stem cell (MSC)-derived exosomes and their role in regenerative processes.
Specifically, Dr. Askenase’s new unpublished preliminary work is focused on the role of MSC-derived exosomes in healing the injured spinal cord in rats.
In this interview, we discuss the growing importance of MSC-derived exosomes, including their advantages and applications. We also explore the market potential for stem cell exosomes, as well as companies competing in this emerging market area.